MicroRNA-155, is an oncogenic miRNA, highly expressed in B-cell malignancies, particularly in the non-Germinal Center B-cell or activated B-cell subtype of Diffuse Large B-cell Lymphoma (non-GCB/ABC-DLBCL), where it is considered a potential diagnostic and prognostic biomarker. Thus, miR-155 inhibition represents an important therapeutic strategy for B-cell lymphomas. In this study, we tested the efficacy and pharmacodynamic activity of an oligonucleotide inhibitor of miR-155, cobomarsen, in ABC-DLBCL cell lines and in corresponding xenograft mouse models. In addition, we assessed the therapeutic efficacy and safety of cobomarsen in a patient diagnosed with aggressive ABC-DLBCL.
Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo / Anastasiadou, Eleni; Seto, Anita; Beatty, Xuan; Hermreck, Melanie; Gilles, Maud-Emmanuelle; Stroopinsky, Dina; Pinter-Brown, Lauren C; Pestano, Linda; Marchese, Cinzia; Avigan, David; Trivedi, Pankaj; Escolar, Diana; Jackson, Aimee; Slack, Frank J. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 27:4(2021), pp. 1139-1149. [10.1158/1078-0432.CCR-20-3139]
Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo
Anastasiadou, EleniPrimo
;Marchese, Cinzia;Trivedi, Pankaj;
2021
Abstract
MicroRNA-155, is an oncogenic miRNA, highly expressed in B-cell malignancies, particularly in the non-Germinal Center B-cell or activated B-cell subtype of Diffuse Large B-cell Lymphoma (non-GCB/ABC-DLBCL), where it is considered a potential diagnostic and prognostic biomarker. Thus, miR-155 inhibition represents an important therapeutic strategy for B-cell lymphomas. In this study, we tested the efficacy and pharmacodynamic activity of an oligonucleotide inhibitor of miR-155, cobomarsen, in ABC-DLBCL cell lines and in corresponding xenograft mouse models. In addition, we assessed the therapeutic efficacy and safety of cobomarsen in a patient diagnosed with aggressive ABC-DLBCL.| File | Dimensione | Formato | |
|---|---|---|---|
|
Anastasiadou_Cobomarsen_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
6.46 MB
Formato
Adobe PDF
|
6.46 MB | Adobe PDF | Contatta l'autore |
|
Anastasiadou_postprint_Cobomarsen_2021.pdf
Open Access dal 19/11/2021
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
6.02 MB
Formato
Adobe PDF
|
6.02 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
